Erschienen in:
01.06.2006 | Editorial
Adjuvant Treatment of Stage II Colon Cancer: Is There a True No-Chemotherapy Group?
verfasst von:
Robert C. G. Martin, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 6/2006
Einloggen, um Zugang zu erhalten
Excerpt
In this issue of
Annals of Surgical Oncology, André et al.
1 present an exhaustive review of the controversial management in the use of adjuvant chemotherapy for stage II colon cancers. The authors review the results of the most recent clinical trials and meta-analyses investigating the value of adjuvant chemotherapy for stage II patients. They emphasize that this is a heterogenous patient population that includes patients with T2, T3, and T4 lesions, tumor perforation, and tumor differentiation, all of whom are believed to be N0. This heterogeneous population is the reason that 5-year survival rates for stage II colon cancer range from a high of 70% to a low of 30%.
2 …